SG11201407599SA - Oligonucleotide chelate complex-polypeptide compositions and methods - Google Patents
Oligonucleotide chelate complex-polypeptide compositions and methodsInfo
- Publication number
- SG11201407599SA SG11201407599SA SG11201407599SA SG11201407599SA SG11201407599SA SG 11201407599S A SG11201407599S A SG 11201407599SA SG 11201407599S A SG11201407599S A SG 11201407599SA SG 11201407599S A SG11201407599S A SG 11201407599SA SG 11201407599S A SG11201407599S A SG 11201407599SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- quebec
- rule
- montreal
- applicant
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 2
- 239000013522 chelant Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 241000220317 Rosa Species 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 150000004697 chelate complex Chemical class 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261648711P | 2012-05-18 | 2012-05-18 | |
| US201261695035P | 2012-08-30 | 2012-08-30 | |
| PCT/CA2013/050379 WO2013170386A1 (en) | 2012-05-18 | 2013-05-17 | Oligonucleotide chelate complex-polypeptide compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407599SA true SG11201407599SA (en) | 2014-12-30 |
Family
ID=49581470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407599SA SG11201407599SA (en) | 2012-05-18 | 2013-05-17 | Oligonucleotide chelate complex-polypeptide compositions and methods |
Country Status (34)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3199635B1 (en) | 2007-05-11 | 2019-02-06 | Adynxx, Inc. | Gene expression and pain |
| CA2872901A1 (en) | 2012-05-10 | 2013-11-14 | Adynxx, Inc. | Formulations for the delivery of active ingredients |
| JP6270846B2 (ja) | 2012-08-30 | 2018-01-31 | ใฌใใชใณใผใซ ใคใณใณใผใใฌใผใใฃใใ | ๏ผขๅ่็ๆๆๅใณ๏ฝๅ่็ๆๆใฎๆฒป็ๆนๆณ |
| KR20170029577A (ko) * | 2014-07-10 | 2017-03-15 | ๋ ํ๋ฆฌ์ฝ๋ฅด ์ธ์ฝํฌ๋ ์ดํฐ๋ | Bํ ๊ฐ์ผ ๋ฐ dํ ๊ฐ์ผ ๋ฐ์ด๋ฌ์ค ๊ฐ์ผ์ ์น๋ฃ ๋ฐฉ๋ฒ |
| CA2957250A1 (en) | 2014-08-15 | 2016-02-18 | Adynxx, Inc. | Oligonucleotide decoys for the treatment of pain |
| SG11202104636XA (en) * | 2018-11-08 | 2021-06-29 | Aligos Therapeutics Inc | S-antigen transport inhibiting oligonucleotide polymers and methods |
| US11166976B2 (en) | 2018-11-08 | 2021-11-09 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| WO2024255846A1 (en) * | 2023-06-16 | 2024-12-19 | Ractigen Therapeutics | Oligonucleotide formulation |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2769114B2 (ja) * | 1993-10-29 | 1998-06-25 | ใตใคใฏใญใผใณใปใใกใผใใทใฅใผใใฃใซใซใบ | ใใใใซ๏ฝๅ่็ๆๆ็ๆฒป็็จๅป่ฌ็ตๆ็ฉ |
| UA78726C2 (en) * | 2001-11-01 | 2007-04-25 | Sciclone Pharmaceuticals Inc | Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment |
| AU2003267785C1 (en) * | 2002-09-13 | 2009-12-24 | Replicor, Inc. | Non-sequence complementary antiviral oligonucleotides |
| WO2004076474A2 (en) * | 2003-02-26 | 2004-09-10 | Intermune, Inc. | Polyethylene glycol modified interferon compositions and methods of use thereof |
| BRPI0415935A (pt) * | 2003-10-27 | 2007-01-02 | Vertex Pharma | combinaรงรตes para tratamento de hcv |
| WO2006042418A1 (en) * | 2004-10-19 | 2006-04-27 | Replicor Inc. | Antiviral oligonucleotides |
| WO2007022642A2 (en) * | 2005-08-25 | 2007-03-01 | Replicor Inc. | Anti-inflammatory molecules and their uses |
| EP1928498A4 (en) * | 2005-09-29 | 2009-11-11 | Cell Biosciences Inc S | METHOD FOR THE TREATMENT OF T-CELL DISORDERS WITH TISF |
| WO2007036016A1 (en) | 2005-09-29 | 2007-04-05 | Replicor Inc. | Therapeutic molecules and their uses |
| GB0715383D0 (en) * | 2007-08-08 | 2007-09-19 | Asterion Ltd | Interferon |
| WO2009065181A1 (en) * | 2007-11-21 | 2009-05-28 | Apollo Life Sciences Limited | Nanostructures suitable for delivery of agents |
| EP2229459B1 (en) | 2007-12-13 | 2014-08-27 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for prevention or treatment of RSV infection |
| EP2268811A1 (en) | 2008-03-07 | 2011-01-05 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
| KR101704988B1 (ko) * | 2009-05-28 | 2017-02-08 | ํ์์์์ด, ์ธํฌ. | ํญ๋ฐ์ด๋ฌ์ค ์ ์ ์์ ๋ํ ์ฒ์ฐ ์ํฐ์ผ์ค ์ ์ฌ์ฒด์ ์ต์ ์ ์ํ ํญ๋ฐ์ด๋ฌ์ค ์ ์ ์ ๊ด๋ จ๋ ์งํ์ ์น๋ฃ |
| EP2512491B1 (en) * | 2009-10-16 | 2017-10-11 | Glaxo Group Limited | Hbv antisense inhibitors |
| SI2605794T1 (sl) * | 2010-08-20 | 2017-01-31 | Replicor Inc. | Oligonukleotidni kelatni kompleksi |
| JP6270846B2 (ja) | 2012-08-30 | 2018-01-31 | ใฌใใชใณใผใซ ใคใณใณใผใใฌใผใใฃใใ | ๏ผขๅ่็ๆๆๅใณ๏ฝๅ่็ๆๆใฎๆฒป็ๆนๆณ |
-
2013
- 2013-05-17 MY MYPI2014003189A patent/MY168778A/en unknown
- 2013-05-17 JP JP2015511877A patent/JP2015517504A/ja active Pending
- 2013-05-17 EP EP13791618.5A patent/EP2849798B1/en active Active
- 2013-05-17 ES ES13791618T patent/ES2873844T3/es active Active
- 2013-05-17 LT LTEP13791618.5T patent/LT2849798T/lt unknown
- 2013-05-17 HU HUE13791618A patent/HUE054875T2/hu unknown
- 2013-05-17 DK DK13791618.5T patent/DK2849798T3/da active
- 2013-05-17 HR HRP20210840TT patent/HRP20210840T1/hr unknown
- 2013-05-17 PT PT137916185T patent/PT2849798T/pt unknown
- 2013-05-17 NZ NZ703095A patent/NZ703095A/en unknown
- 2013-05-17 SM SM20210319T patent/SMT202100319T1/it unknown
- 2013-05-17 SG SG11201407599SA patent/SG11201407599SA/en unknown
- 2013-05-17 AU AU2013262416A patent/AU2013262416B2/en active Active
- 2013-05-17 CN CN201380026009.3A patent/CN104349793B/zh active Active
- 2013-05-17 CA CA2873529A patent/CA2873529C/en active Active
- 2013-05-17 SI SI201331881T patent/SI2849798T1/sl unknown
- 2013-05-17 BR BR112014028654A patent/BR112014028654A2/pt active Search and Examination
- 2013-05-17 WO PCT/CA2013/050379 patent/WO2013170386A1/en not_active Ceased
- 2013-05-17 KR KR1020147035252A patent/KR102068109B1/ko active Active
- 2013-05-17 TW TW102117594A patent/TWI635864B/zh not_active IP Right Cessation
- 2013-05-17 US US13/896,510 patent/US9492506B2/en active Active
- 2013-05-17 PL PL13791618T patent/PL2849798T3/pl unknown
- 2013-05-17 EA EA201401278A patent/EA035967B1/ru unknown
- 2013-05-17 MX MX2014014021A patent/MX346239B/es active IP Right Grant
- 2013-05-17 RS RS20210674A patent/RS62030B1/sr unknown
-
2014
- 2014-11-06 IL IL235548A patent/IL235548B/en active IP Right Grant
- 2014-11-14 PH PH12014502551A patent/PH12014502551B1/en unknown
- 2014-11-18 DO DO2014000264A patent/DOP2014000264A/es unknown
- 2014-11-18 EC ECIEPI201427694A patent/ECSP14027694A/es unknown
- 2014-11-18 CL CL2014003134A patent/CL2014003134A1/es unknown
- 2014-11-18 CR CR20140527A patent/CR20140527A/es unknown
- 2014-11-19 CO CO14254322A patent/CO7131387A2/es unknown
- 2014-11-25 ZA ZA2014/08674A patent/ZA201408674B/en unknown
-
2021
- 2021-05-31 CY CY20211100467T patent/CY1124345T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407599SA (en) | Oligonucleotide chelate complex-polypeptide compositions and methods | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201408646VA (en) | Dimeric protein with triple mutations | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201408261UA (en) | Syringe | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201407261XA (en) | Oligonucleotide chelate complex methods | |
| SG11201908650PA (en) | Optimized antibody compositions for treatment of ocular disorders | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201407669QA (en) | Methods for improving safety of blood-brain barrier transport | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions | |
| SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments |